In this article, my colleagues and I provided an overview of CD38 as a therapeutic target in myeloma and reviewed available preclinical and clinical data on daratumumab, the first-in-class human anti-CD38 mAb approved for the treatment of MM. https://t.co/
Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma https://t.co/6CduwxTtPb
RT @SeeFisch: Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. - PubMed - NCBI https://t.co/mJ…
RT @SeeFisch: Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. - PubMed - NCBI https://t.co/mJ…
RT @SeeFisch: Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. - PubMed - NCBI https://t.co/mJ…
RT @SeeFisch: Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. - PubMed - NCBI https://t.co/mJ…
Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. - PubMed - NCBI https://t.co/mJqDdvXM9Z